Articles

P3.13 Plerixafor in autologous haematopoietic stem cell mobilization in Belgium

BJH - volume 6, issue Abstract Book BHS, january 2015

D. Selleslag MD, C. Lambert MD, P. Zachée MD, PhD, D. Dierickx MD, PhD

Read more

P2.09 Refractory anemia with ringed sideroblasts upon linezolid treatment

BJH - volume 6, issue Abstract Book BHS, january 2015

K. Vanhouteghem PharmD, B. Cauwelier MD, PhD, P. Costers , D. Selleslag MD, J. Emmerechts MD, PhD

Read more

P3.05 Efficacy of azacitidine in Belgian patients: results of a real-life non-interventional, post-marketing survey

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Meers MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD, C. Graux MD, PhD, G. Bries MD, PhD, D. Deeren , I. Vrelust MD, P. Pierre , C. Ravoet , K. Theunissen MD, F. Trullemans , L. Noens MD, PhD, P. Mineur MD

Read more

P2.10 BRAF V600E mutation is not a disease-defining genetic event in classic hairy cell leukemia

BJH - volume 5, issue Abstract Book BHS, january 2014

F. Nollet PhD, MSc, K. Boon , J. Emmerechts MD, PhD, S. Vermeire , R. D’Hondt , A. Van Hoof MD, PhD, D. Selleslag MD, J. Van Droogenbroeck MD, T. Lodewyck MD, J. Billiet MD

Read more

P2.07 Bing-Neel syndrome: report of two cases

BJH - volume 5, issue Abstract Book BHS, january 2014

E. Dumoulin PharmD, B. Depreter PhD, PharmD, L. Vanopdenbosch MD, J. Emmerechts MD, PhD, F. Nollet PhD, MSc, D. Selleslag MD, A. Van Hoof MD, PhD, J. Billiet MD

Read more

Primary immune thrombocytopenia in adults

BJH - volume 4, issue 1, march 2013

A. Janssens MD, PhD, C. Lambert MD, G. Bries MD, PhD, A. Bosly MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Summary

The Belgian Hematological Society (BHS) guideline panel on adult primary immune thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to make recommendations on the best strategies for frontline and subsequent-line treatment. No treatment is necessary for patients with platelet counts higher than 30000/μl in the absence of bleeding symptoms. Patients newly diagnosed or relapsing after a long-term treatment-free period can be managed with corticosteroids with or without intravenous immunoglobulins. A second line therapy is indicated for those patients who are intolerant or unresponsive to or relapse after initial corticosteroid treatment and have a risk of bleeding. The guideline panel recommends splenectomy as it is the treatment with the highest curative potential and an acceptable safety profile. If possible, splenectomy should be delayed to at least twelve months after diagnosis as spontaneous remission can occur in this time period. Thrombopoietin receptor (TPO-R) agonists are recommended for patients who are refractory to or relapse after splenectomy or who have a contra-indication to splenectomy irrespective of the duration of ITP. The guideline panel agrees that rituximab, azathioprine, cyclophosphamide, cyclosporine A, danazol, dapsone, mycophenolate mofetil and vincristine/vinblastine are potential treatment options, especially for patients refractory to TPO-R agonists.

(BELG J HEMATOL 2013;1:11–20)

Read more

Intravascular large B-cell lymphoma: four case reports from a single centre and review of literature

BJH - volume 3, issue 4, december 2012

S. Drieghe PharmD, B. Cauwelier MD, PhD, T. Lodewyck MD, D. Selleslag MD, J. Van Droogenbroeck MD, A. Van Hoof MD, PhD, J. Van Huysse MD, J. Billiet MD

Summary

Intravascular lymphoma is a rare haematological malignancy characterised by neoplastic proliferation of lymphoid cells particularly within the lumina of capillaries, heterogeneity in clinical presentation, disseminated disease with aggressive behaviour and often fatal course. In the present case report, we describe four cases of intravascular lymphoma diagnosed in a single centre over a period of ten years.

(BELG J HEMATOL 2012;3: 149–154)

Read more